Vivos Therapeutics Unveils New Model

Vivos Therapeutics(NASDAQ:VVOS) reported second quarter 2025 results on August 20, 2025, marking a pivotal shift from its legacy dentist-focused model to a direct, patient-centric sleep center strategy. Revenue declined 6% year over year to $3.8 million, but the recent acquisition of the Sleep Center of Nevada (SCN) contributed $500,000 in service revenue in just 20 days, and management highlighted rapid operational integration and strong patient demand. The company raised $11.5 million in new capital to fund this transition, but operating loss widened to $4.9 million as Vivos Therapeutics invested in scaling its new model.SCN, acquired in June 2025, historically served over 200,000 obstructive sleep apnea (OSA) patients since 2019, providing a large patient funnel as Vivos Therapeutics transitions away from its legacy VIP (dentist training) revenue. The company reported $500,000 in incremental sleep testing revenue from SCN in just 20 post-close days, and is already expanding facilities and staff to meet demand.This early validation of the new model, with strong provider buy-in and patient demand, suggests Vivos Therapeutics could accelerate its transition to a vertically integrated, recurring-revenue business and reduce reliance on legacy dentist enrollment fees.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool